Type 2 Innovation Grant 2021
Opens Feb 1 2021 12:00 AM (CET)
Deadline May 31 2021 11:59 PM (CEST)
Description

SUBMIT YOUR APPLICATION NOW

Independent research is crucial in discovering new ways to improve human health. That’s why, at Sanofi Genzyme and Regeneron, we are taking an active role in helping research initiatives become a reality by offering research grants to ten innovative projects designed to improve the lives of people with immune-mediated diseases (the “Type 2 Innovation Grant”). 

We have involved IntraMed Communications S.r.l., located at Via Raffaello Bertieri 4, 20146 Milan, Italy (“IntraMed”) to operate and manage the Type 2 Innovation Grant on our behalf.  

If you are interested in participating in the 2021 edition of the Type 2 Innovation Grant, check “The research grant” tab for more information or contact us by clicking the "Information" tab.

IMPORTANT INFORMATION TO ALL APPLICANTS:

We would like to inform you that due to personal reasons one expert from the Respiratory panel is no longer able to take part in the review process. For consistency, Sanofi Genzyme and Regeneron have assigned the review process to the other 5 experts of the Respiratory panel. In spite of this, rest assured that the reviewing criteria and timing the experts have to follow, specified in the rules of the program (The Research Grant tab), will not be subject to any change.






Privacy Policy
Rules of Participation
Terms of use
Cookie Policy




This site is intended for European Health Care Professionals only.

Sanofi Genzyme and Regeneron are committed to providing resources to advance research in areas of unmet medical need among patients with inflammatory and immunologic diseases. 

© 2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-EU-2100041 January 2021

Type 2 Innovation Grant 2021


SUBMIT YOUR APPLICATION NOW

Independent research is crucial in discovering new ways to improve human health. That’s why, at Sanofi Genzyme and Regeneron, we are taking an active role in helping research initiatives become a reality by offering research grants to ten innovative projects designed to improve the lives of people with immune-mediated diseases (the “Type 2 Innovation Grant”). 

We have involved IntraMed Communications S.r.l., located at Via Raffaello Bertieri 4, 20146 Milan, Italy (“IntraMed”) to operate and manage the Type 2 Innovation Grant on our behalf.  

If you are interested in participating in the 2021 edition of the Type 2 Innovation Grant, check “The research grant” tab for more information or contact us by clicking the "Information" tab.

IMPORTANT INFORMATION TO ALL APPLICANTS:

We would like to inform you that due to personal reasons one expert from the Respiratory panel is no longer able to take part in the review process. For consistency, Sanofi Genzyme and Regeneron have assigned the review process to the other 5 experts of the Respiratory panel. In spite of this, rest assured that the reviewing criteria and timing the experts have to follow, specified in the rules of the program (The Research Grant tab), will not be subject to any change.






Privacy Policy
Rules of Participation
Terms of use
Cookie Policy




This site is intended for European Health Care Professionals only.

Sanofi Genzyme and Regeneron are committed to providing resources to advance research in areas of unmet medical need among patients with inflammatory and immunologic diseases. 

© 2021 Sanofi and Regeneron Pharmaceuticals, Inc. All Rights Reserved. MAT-EU-2100041 January 2021

Opens
Feb 1 2021 12:00 AM (CET)
Deadline
May 31 2021 11:59 PM (CEST)